Israeli startup PhaseV, an AI-enabled clinical development company for life sciences, has secured $50 million in Series A funding in a round co-led by Accel and Insight Partners. Existing investors Viola Ventures, LionBird and EXOR…
Continue Reading
What You Should Know:
– PhaseV, a company at the forefront of applying artificial intelligence (AI) and machine learning (ML) to clinical development raies $50M in Series A funding round co-led by Accel and Insight…
Continue Reading
Today PayZen, a technology company tackling healthcare affordability with AI-powered solutions, announced an oversubscribed Series B, led by NEA, with full participation from existing investors including 7wireVentures, SignalFire, Viola Ventures, and others. The round…
Continue Reading
Clinical Trial Platform Uncovers Hidden Signals and Optimizes Next Steps for More Adaptive, Successful, and Efficient Clinical Trials
PhaseV, a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that it has…
